Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab consolidation in multiple myeloma with residual disease
2015-003359-23Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoint: Upgrade of response. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-003359-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003359-23.